Compounds > e-6087
Page last updated: 2024-11-12

e-6087

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

enflicoxib: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9953093
SCHEMBL ID26427
MeSH IDM0415452

Synonyms (18)

Synonym
SCHEMBL26427
1-(4-aminosulphonylphenyl)-5-(2,4-difluorophenyl)-4,5-dihydro-3-trifluoromethyl-1h-pyrazole
e-6087
unii-vm9pyq1mqg
4-(5-(2,4-difluorophenyl)-3-(trifluoromethyl)-4,5-dihydro-1h-pyrazol-1-yl)benzenesulfonamide
MS-26929
VM9PYQ1MQG ,
251442-94-1
benzenesulfonamide, 4-(5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1h-pyrazol-1-yl)-
4-(3-(2,4-difluorophenyl)-5-(trifluoromethyl)-3,4-dihydropyrazol-2-yl)benzenesulfonamide
enflicoxib [inn]
enflicoxib
e-6087, (+/-)-
1-(4-aminosulfonylphenyl)-5-(2,4-difluorophenyl)-4,5-dihydro-3-trifluoromethyl-1h-pyrazole
4-[3-(2,4-difluorophenyl)-5-(trifluoromethyl)-3,4-dihydropyrazol-2-yl]benzenesulfonamide
CS-0015483
HY-19384
AKOS040748300

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" No differences in the incidence of adverse reactions were detected among the different groups."( Efficacy and safety of enflicoxib for treatment of canine osteoarthritis: A 6-week randomised, controlled, blind, multicentre clinical trial.
Badiella, L; Homedes, J; Salichs, M; Sarasola, P, 2022)		0.72
"Enflicoxib administered weekly for 6 weeks, at 4 mg/kg PO with an initial loading dose of 8 mg/kg, is efficacious and safe for the treatment of canine osteoarthritis."( Efficacy and safety of enflicoxib for treatment of canine osteoarthritis: A 6-week randomised, controlled, blind, multicentre clinical trial.
Badiella, L; Homedes, J; Salichs, M; Sarasola, P, 2022)		0.72

Pharmacokinetics

ExcerptReferenceRelevance
" In both animal species, E-6087 was characterized by a long elimination half-life (20-35 h), a low plasma clearance (0."( Pharmacokinetics of E-6087, a new anti-inflammatory agent, in rats and dogs.
Farrán, R; García-Soret, A; Martínez, L; Moragón, T; Reinoso, RF, 2001)		0.94
" The optimal therapeutic dose to be confirmed in the field studies was established using a combination of pharmacokinetic (PK) modelling and pharmacodynamic (PD) studies."( Pharmacology of enflicoxib, a new coxib drug: Efficacy and dose determination by clinical and pharmacokinetic-guided approach for the treatment of osteoarthritis in dogs based on an acute arthritis induction model.
Cendrós, JM; Encina, G; Homedes, JM; Salichs, M; Vela, JM, 2022)		0.72

Bioavailability

ExcerptReferenceRelevance
" Oral bioavailability was lower in dogs than in rats whereas a faster elimination was found in rats."( Pharmacokinetics of E-6087, a new anti-inflammatory agent, in rats and dogs.
Farrán, R; García-Soret, A; Martínez, L; Moragón, T; Reinoso, RF, 2001)		0.63

Dosage Studied

ExcerptRelevanceReference
" After oral dosing of 1, 5 and 25 mg kg(-1) to rats, linearity was lost at the highest dose due to the low aqueous solubility of E-6087."( Pharmacokinetics of E-6087, a new anti-inflammatory agent, in rats and dogs.
Farrán, R; García-Soret, A; Martínez, L; Moragón, T; Reinoso, RF, 2001)		0.84
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (50.00)29.6817
2010's0 (0.00)24.3611
2020's5 (50.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.79

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.79 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.79)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (20.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
methanol
Methanol: A colorless, flammable liquid used in the manufacture of FORMALDEHYDE and ACETIC ACID, in chemical synthesis, antifreeze, and as a solvent. Ingestion of methanol is toxic and may cause blindness.. primary alcohol : A primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.. methanol : The primary alcohol that is the simplest aliphatic alcohol, comprising a methyl and an alcohol group.		2.4220alkyl alcohol;
one-carbon compound;
primary alcohol;
volatile organic compound		amphiprotic solvent;
Escherichia coli metabolite;
fuel;
human metabolite;
mouse metabolite;
Mycoplasma genitalium metabolite
betadex
beta-Cyclodextrins: Cyclic GLUCANS consisting of seven (7) glucopyranose units linked by 1,4-glycosidic bonds.		2.0110cyclodextrin
4-(5-(4-fluorophenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl)benzenesulfonamide
4-(5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide: a long-acting COX-2 inhibitor; structure in first source. mavacoxib : A member of the class of pyrazoles that is 1H-pyrazole which is substituted at positions 1, 3 and 5 by 4-sulfamoylphenyl, trifluoromethyl and 4-fluorophenyl groups, respectively. A selective cyclooxygenase 2 inhibitor, it is used in veterinary medicine to treat pain and inflammation in dogs with degenerative joint disease.		3.811organofluorine compound;
pyrazoles;
sulfonamide		cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
ConditionIndicatedRelationship StrengthStudiesTrials
Canine Diseases
[description not available]		04.4931
Arthritis, Degenerative
[description not available]		04.4931
Ache
[description not available]		04.2121
Osteoarthritis
A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans.		04.4931
Pain
An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.		04.2121
Innate Inflammatory Response
[description not available]		03.811
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		03.811
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		0210